Despite today's decline, the ASX biopharmaceutical company's shares have rebounded a whopping 68% since dropping to a multi-year low of $8.63 in mid-February.

Telix shares are now up 27% for the year-to-date, but they're still 43% lower than this time last year.

What has pushed the shares higher over the past 9 weeks?

After bottoming out in mid-February, Telix shares have rebounded following a flurry of consecutive good-news updates.

In late-February, the company confirmed that it had filed a key regulatory approval in Europe.

Later in March, Telix posted several announcements about its growth and development plans. 

It released positive Part 1 results from its global Phase 3 ProstACT study of TLX591-Tx, its novel prostate cancer therapy in early-March.

The following week, Telix announced it had resubmitted its New Drug Application (NDA) to the U.S. FDA for TLX101-Px (Pixclara®), a brain cancer imaging candidate. Telix's resubmission includes new data addressing the US Food and Drug Administration (FDA)'s previous requests. 

The good news continued on through April, too.

On the 10th of April, the company announced that the FDA has accepted its NDA for TLX101-Px (Pixclara®).

Just a few days later, Telix announced a major collaboration with US-based Regeneron Pharmaceuticals. The two companies entered a 50/50 global cost and profit-sharing agreement to co-develop radiopharmaceutical therapies targeting solid tumours.

Last week, the biopharma company released an investor presentation which revealed a 56% increase in group revenue and underlying profitability supported by a positive cash balance of US$142 million. Telix also issued FY26 revenue guidance in the range of US$950 million to US$970 million.

The company has also priced and increased its US$600 million convertible bond offering, up from US$550 million due to strong global investor demand.

The flurry of good news has caused a positive swing of sentiment and it looks like many are now buying back into the biopharmaceutical's shares while they are trading for cheap.

What's next for Telix shares? Are they a buy, sell or hold?

Telix shares are widely considered oversold and undervalued, with brokers tipping a significant upside ahead.

TradingView data shows that brokers have a consensus buy/strong buy rating on the shares, with an average target price of $24.44. At the time of writing that implies a 70% upside over the next 12 months.

Some are even more optimistic that the latest rally of positive updates out of Telix will translate into strong growth this year. The maximum target price is $31.01, which translates to a 114% upside at the time of writing.

The post Up 68% from a multi-year low. Are Telix shares a buy, sell or hold? appeared first on The Motley Fool Australia.

It's often assumed that because these companies are well-established, there is limited upside. 

However, here are some blue-chip stocks that have recently received price targets from brokers indicating upside of 20% or more. 

Qantas Airways Ltd (ASX: QAN)

With oil prices skyrocketing and geopolitical tension impacting global travel, Qantas shares have faced some volatility recently. 

The company noted that it is facing uncertainty due to Middle East tensions and rising jet fuel refining margins. 

However, it has hedged crude oil exposure and remains confident in fuel supply through April and May. 

Strong international demand – especially to Europe – has led the airline to redeploy aircraft and cut domestic capacity, with higher airfares expected to lift unit revenue by about 5% in the second half of FY26.

These headwinds have pushed its stock price down by 12% year to date. 

In good news for prospective buyers, the Qantas share price could now be a significant value. 

Macquarie recently placed a $11 price target on the airline's shares, which would be a 20% rise from the share price at the time of writing. 

As a bonus, experts are tipping a healthy dividend yield for the ASX 200 company throughout the next few years. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Like many ASX 200 healthcare shares, the Telix stock price has fallen heavily in the last 12 months. 

However, the commercial-stage biopharmaceutical company has rebounded significantly over the past month. 

Brokers believe this could be the start of a longer rally. 

Recently, Bell Potter placed a buy rating and $19 price target on Telix shares after the company announced the refinancing of its convertible note facility. 

The share price at the time of writing is hovering around $14.59, which indicates an upside potential of 30%. 

Life360 Inc (ASX: 360)

Despite now climbing 26% over the last 6 days at the time of writing, the Life360 share price remains significantly below its yearly highs. 

The company's core product is a private family and friends social networking app that allows users to communicate and share their locations.

At the time of writing, this ASX 200 stock is exchanging hands for $22.72 per share. 

However, this is significantly below the $36.02 average price targets of 10 analysts via TradingView. 

Should this ASX 200 stock reach that level in the next 12 months, it would be a 58% rise from current levels. 

The post 3 ASX 200 shares tipped to rise 20% or more appeared first on The Motley Fool Australia.

This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.

With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:

• Domino's Pizza Enterprises Ltd (ASX: DMP) remains the most shorted ASX share after its short interest rose to 15.4%. This pizza chain operator is undertaking a turnaround strategy and short sellers don't appear confident it will succeed.
• Telix Pharmaceuticals Ltd (ASX: TLX) has short interest of 13.9%, which is down since last week. Short sellers may be betting against this radiopharmaceuticals company successfully getting its products approved by the US FDA.
• Guzman Y Gomez Ltd (ASX: GYG) has short interest of 13.8%, which is up week on week. Short sellers aren't giving up on this quick service restaurant operator despite its shares rocketing this month after reporting a big improvement in its performance.
• Polynovo Ltd (ASX: PNV) has 13.7% of its shares held short, which is down since last week. Short sellers seem to think this medical device company's shares are overvalued. However, both Bell Potter and Morgans believe they could rise approximately 80%.
• Treasury Wine Estates Ltd (ASX: TWE) has seen its short interest rise to 13%. This is likely to have been driven by concerns that the wine giant will continue to struggle with consumer spending pressures and distributor disruption.
• Flight Centre Travel Group Ltd (ASX: FLT) has short interest of 12.9%, which is up week on week. Short sellers appear to believe that travel demand could be impacted by the Middle East conflict.
• DroneShield Ltd (ASX: DRO) has 12.7% of its shares held short, which is up since last week. This counter drone technology company recently announced the sudden exit of its CEO and chair. This disruption and valuation concerns could be weighing on sentiment.
• Zip Co Ltd (ASX: ZIP) has short interest of 12.5%. Unfortunately for short sellers, this buy now pay later provider impressed the market with its quarterly update last week.
• Boss Energy Ltd (ASX: BOE) has short interest of 11.5%, which is down since last week. This uranium miner's production outlook is uncertain beyond 2026. Short sellers appear to be betting on production falling more than the market is predicting.
• Lotus Resources Ltd (ASX: LOT) has entered the top ten with short interest of 11%. It is another uranium producer that short sellers are targeting.

The post These are the 10 most shorted ASX shares appeared first on The Motley Fool Australia.

That's the view of analysts at Bell Potter, who are tipping the radiopharmaceuticals company as a top buy this week.

What is the broker saying?

Bell Potter notes that Telix has announced the refinancing of its convertible note facility. It is pleased with the decision and believes it removes an overhang on its shares. It explains:

TLX has refinanced its A$650m convertible note (CN) facility with a freshly negotiated US$600m CN facility. The major advantage for TLX is the long term deferral of the pending investor put option on the original facility. The put option had an exercise date in July 2027 with the share price currently well below the estimated conversion price of A$24.75, hence it is reasonable to believe note holders could have taken cash rather than continue to hold the notes. The refinance has been completed to remove this overhang, providing shareholders with greater certainty.

The expanded principal balance also provides the company with greater flexibility on its future funding requirement. The new facility also has a 5- year term with a put option after 3 years and coupon of 1.5%. The use of debt to partly fund the drug development program remains a higher risk strategy. Approval of both Pixclara and Zircaix later this year remain important catalysts for note holders. The key risk is the prospect of further delays to approvals which would inevitably cause earnings downgrades and downward pressure on the share price.

The broker was also pleased with news that Telix has signed a co-development and co-commercialisation agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN). It adds:

The CN refinance comes fast on the heels of the co-development and co-commercialisation deal with Regeneron announced earlier this week. Regeneron are a tier one pharma company in the US with revenues exceeding US$14bn in 2025 and market cap of US$80bn. Nevertheless, Regeneron is like most other large pharma – seeking to replace lost revenues from recent patent cliffs.

It does not currently have revenues from any molecularly target radiation, however, it does have a large oncology franchise. TLX will receive a US$40m upfront fee which we expect it will amortise over several years. First indication could include a combination with Regeneron's Libtayo for the treatment of Non-small Cell Lung Cancer.

Are Telix shares heading to $19?

According to the note, the broker has retained its buy rating and $19.00 price target on Telix's shares.

Based on its current share price of $15.00, this implies potential upside of almost 27% for investors over the next 12 months.

The broker concludes:

TP remains unchanged at $19.00. No changes to revenues. FY26 EBITDA is increased by $8m being the estimated FY26 revenue from the Regeneron agreement. There are minor changes to the finance charge in line with revised terms on the CN facility. We retain our Buy rating.

The post Is the Telix share price heading to $19? This broker thinks it is appeared first on The Motley Fool Australia.

Four ASX shares that have failed to follow the market higher today are listed below. Here's why they are falling:

Boss Energy Ltd (ASX: BOE)

The Boss Energy share price is down 11% to $1.54. Investors have been selling the uranium producer's shares after it downgraded its guidance. Boss Energy now expects FY 2026 production for the Honeymoon operation to be between 1.40 million and 1.45 million pounds of U3O8. This is down from previous guidance of 1.6 million pounds. The company's managing director, Matthew Dusci, said: "We recognise this downgrade is disappointing, particularly after maintaining guidance as recently as March. At that time, our expectation was that site access and reagent deliveries would normalise during the month. Subsequent unexpected rainfall, combined with the degraded baseline condition of access roads, extended disruption materially beyond that assumption. This has impacted both production and the timing of commissioning critical infrastructure during ramp-up."

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is down 6% to $14.50. This has been driven by news that the radiopharmaceuticals company is raising US$600 million through a convertible bonds offering. The bonds are expected to carry a relatively low coupon of between 1.50% and 1.75% and will be issued with a conversion price of US$13.85 (~A$19.55). This is a premium of approximately 37.5% to the current share price. Telix's managing director and group CEO, Dr. Christian Behrenbruch, said: "The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds."

Woodside Energy Group Ltd (ASX: WDS)

The Woodside Energy share price is down 2.5% to $33.13. Investors have been selling the energy producer's shares today in response to reports that the US and Iran have re-entered peace talks. This caused oil prices to tumble overnight. It isn't just Woodside shares that are falling. The S&P/ASX 200 Energy index is down 2% at the time of writing.

Yancoal Australia Ltd (ASX: YAL)

The Yancoal Australia share price is down 2.5% to $7.06. This is despite the coal miner announcing a major acquisition today. Yancoal revealed that it has agreed to acquire an 80% interest in the Kestrel coal mine in Queensland's Bowen Basin for up to US$2.4 billion. This includes an upfront payment of US$1.85 billion, as well as contingent payments of up to US$550 million that are linked to future coal prices.

The post Why Boss Energy, Telix, Woodside, and Yancoal shares are falling today appeared first on The Motley Fool Australia.

At the time of writing, the ASX radiopharmaceuticals stock is down 7.5% to $14.28.

As a comparison, the ASX 200 index is trading 0.25% higher in morning trade today.

Why are Telix shares falling today?

The company's shares are under pressure following the announcement of a large convertible bond offering due in 2031.

According to the release, Telix has raised US$600 million from the convertible notes offering.

These notes can be converted into ordinary Telix shares at a future date, which introduces the potential for dilution if conversion occurs.

Management noted that the proceeds will primarily be used to refinance its existing convertible bonds due 2029, with any excess funds directed toward general corporate purposes.

The bonds are expected to carry a relatively low coupon of between 1.50% and 1.75% and will be issued with a conversion price of US$13.85 (~A$19.55), which is a premium of approximately 37.5% to the current share price.

While the company described the transaction as cost-effective financing, the combination of potential dilution and associated hedging activity appears to be weighing on sentiment.

Telix's managing director and group CEO, Dr. Christian Behrenbruch, said:

The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.

The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.

Investor presentation

Alongside the announcement, Telix also released an updated investor presentation, which largely reiterated previously disclosed performance and outlook details.

The presentation highlights that the company generated group revenue of US$230 million in the first quarter of 2026, representing an 11% increase on the previous quarter and a 23.7% jump on the prior corresponding period.

Looking ahead, Telix continues to guide to FY 2026 revenue in the range of US$950 million to US$970 million. This will be supported by growth in its Precision Medicine business and contributions from its radiopharmacy operations.

Its research and development guidance range remains US$200 million to US$240 million.

And this appears to be money well spent. The company pointed to progress across its pipeline, including multiple late-stage clinical programs and upcoming regulatory milestones.

It also spoke about its significant market opportunity in the US market. Management estimates that it has a US$32 billion addressable market across its Precision Medicine and Therapeutics pipeline.

The post Why are Telix shares sinking 7.5% today? appeared first on The Motley Fool Australia.

What did Telix Pharmaceuticals report?

• US$600 million of 1.50% convertible bonds due 2031, upsized from US$550 million
• Initial conversion price set at US$13.85 (~A$19.55) per ordinary share, a 37.5% premium to reference price
• Interest payable quarterly, beginning 22 July 2026
• Concurrent repurchase of approximately A$637 million of existing A$650 million convertible bonds due 2029
• Settlement of the new issuance and repurchase expected on 22 April 2026

What else do investors need to know?

The offering attracted strong support from both existing and new eligible investors worldwide, reinforcing Telix's reputation in the global capital markets. The convertible bonds will be convertible into fully paid ordinary shares, providing potential upside for bondholders if Telix's share price performs well over the next five years.

As part of its refinancing, Telix is also repurchasing and cancelling over 85% of its outstanding 2029 convertible bonds. The company intends to redeem the remaining bonds, further streamlining its capital structure and reducing refinancing risk.

What did Telix Pharmaceuticals management say?

Managing Director and Group CEO Dr. Christian Behrenbruch, said:

The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.

What's next for Telix Pharmaceuticals?

Looking ahead, Telix expects the completion of the bond issue and concurrent repurchase to enhance its capital management. These actions offer additional financial flexibility as the company pursues development and commercialisation of its radiopharmaceutical portfolio across multiple international markets.

Telix plans to continue investing in its late-stage clinical programmes and expansion, using the strengthened balance sheet to address unmet needs in oncology and rare diseases.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 41%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 15% over the same period.

View Original Announcement

The post Telix Pharmaceuticals upsizes convertible bonds to US$600 million appeared first on The Motley Fool Australia.

What did Telix Pharmaceuticals report?

• Group revenue of US$804 million, up 56% from FY25, meeting upgraded guidance
• Precision Medicine revenue rose 22% year on year to US$622 million
• RLS Radiopharmacies contributed US$170 million in revenue after acquisition
• Group EBITDA of US$40 million
• Positive cash balance of US$142 million as at year end
• Investment of over US$500 million across R&D and strategic initiatives

What else do investors need to know?

Telix's commercial momentum continues, with Q1 2026 unaudited group revenue climbing 11% quarter on quarter to US$230 million. The company is progressing multiple clinical-stage assets, with four therapies now in pivotal or phase 3 trials targeting prostate, kidney, and brain cancers.

Regulatory advances have been made for new products, including Pixclara (TLX101-Px), which has a US FDA target decision date of 11 September 2026, and Illuccix accepted for review in China. Telix has also signed a new global collaboration with Regeneron to co-develop radiopharmaceutical therapies for solid tumours, bringing in US$40 million upfront with potential for further milestone payments.

What's next for Telix Pharmaceuticals?

Looking ahead, Telix has issued FY26 revenue guidance in the range of US$950 million to US$970 million, with continued growth expected in its Precision Medicine segment and full-year contributions from recent acquisitions. R&D investment is targeted between US$200 million and US$240 million, mainly focused on advancing late-stage therapeutics and delivery of clinical milestones.

The company aims to launch new precision imaging and therapy products, complete key clinical trials, and enhance its manufacturing capacity with projects underway in Europe and Japan. Management emphasises reinvesting earnings to support long-term sustainable growth and innovation in radiopharma.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have risen 41%, underperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances appeared first on The Motley Fool Australia.

Will the market be able to build on this on Wednesday? Here are five things to watch:

ASX 200 to rise again

The Australian share market looks set to rise again on Wednesday following a strong night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 47 points or 0.5% higher. In the United States, the Dow Jones rose 0.65%, the S&P 500 climbed 1.2%, and the Nasdaq jumped 1.95%.

Oil prices sink

ASX 200 energy shares such as Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a poor session after oil prices sank overnight. According to Bloomberg, the WTI crude oil price is down 6.95% to US$92.20 a barrel and the Brent crude oil price is down 4.4% to US$88.85 a barrel. The catalyst for this was optimism that a US-Iran peace deal could be on the way.

Telix shares on watch

Telix Pharmaceuticals Ltd (ASX: TLX) shares will be on watch on Wednesday after the radiopharmaceuticals company announced a US$550 million convertible notes offering. The company's managing director and CEO, Dr. Christian Behrenbruch, said: "The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing." Telix notes that the new convertible bonds represent attractive, low-cost financing and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix's current share price.

Gold price rises

ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a good session on Wednesday after the gold price stormed higher overnight. According to CNBC, the gold futures price is up 2% to US$4,864.5 an ounce. This was driven by confirmation that a second round of US-Iran peace talks are taking place.

Mineral Resources shares downgraded

Morgans has downgraded Mineral Resources Ltd (ASX: MIN) shares this week. According to the note, the broker has reduced its rating to accumulate (from buy) and cut its price target to $67.00 (from $68.00). It said: "We have updated our 2H26 forecasts to reflect weather impacts in 3Q26, which we expect to have a modest effect on Onslow iron ore shipments, alongside minor increases to cost and capex assumptions driven by inflation in shipping and fuel."

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back today are listed below. Here's why they are rising:

Monash IVF Group Ltd (ASX: MVF)

The Monash IVF share price is up 14% to 75.7 cents. This morning, the fertility treatment company revealed that it has received a new non-binding takeover proposal from a consortium that includes Washington H. Soul Pattinson and Co Ltd (ASX: SOL). The consortium had previously offered 80 cents per share. This has now been increased to 90 cents per share and "represents the highest amount the Consortium is prepared to offer as its Offer Price, absent a competing proposal emerging for all or a material part of Monash IVF." The company advised that its board is assessing the proposal, including obtaining advice from its financial and legal advisers.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is up 5% to $133.14. This morning, the health imaging technology company announced that it has signed a five-year contract renewal with Northwestern Medicine. Importantly, the $37 million contract has increased minimums and an increased fee per transaction. Commenting on the deal, Pro Medicus' CEO, Dr Hupert, said: "We are extremely pleased that in addition to committing to a second five-year term at an increased fee per exam, NM have also committed to an increase in their minimums reflecting the growth in their exam volumes since standardising on our platform five years ago."

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is up 8% to $15.87. Investors have been buying the radiopharmaceuticals company's shares after it announced a major collaboration with US-based Regeneron Pharmaceuticals (NASDAQ: REGN). The company notes that there is potential to earn up to US$2.1 billion in development and commercial milestone payments plus low double-digit royalties if Telix opts out of co-funding any program. Telix's managing director and CEO, Christian Behrenbruch, said: "The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients."

Woodside Energy Group Ltd (ASX: WDS)

The Woodside Energy share price is up almost 3% to $34.19. This energy giant's shares are rising today after oil prices jumped above US$100 a barrel. The catalyst for the jump was news that US President Donald Trump is threatening to blockade Iranian ports after initial peace talks between the two countries failed.

The post Why Monash IVF, Pro Medicus, Telix, and Woodside shares are storming higher today appeared first on The Motley Fool Australia.

Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed on Friday trading for $14.64. In early morning trade on Monday, shares are swapping hands for $15.39 apiece, up 5.1%.

For some context, the ASX 200 is down 0.8% at this same time.

Here's what's catching investor interest.

Telix share price jumps on collaboration deal

The Telix share price is charging higher after the company announced it has entered into a strategic collaboration with United States based biotech giant Regeneron Pharmaceuticals Inc (NASDAQ: REGN) for cancer treatment.

The agreement will see the companies work together to jointly develop and commercialise next generation radiopharmaceutical therapies.

Management said the 50/50 cost and profit-sharing model combines Telix's radiopharmaceutical development and manufacturing capabilities with Regeneron's antibody discovery platforms and oncology experience.

The collaboration will include multiple solid tumour targets from Regeneron's portfolio of antibodies. The companies said they also intend to develop radio-diagnostics to support patient selection and treatment response assessment.

The new agreement could see Telix earn development and commercial milestone payments of up to US$2.1 billion (AU$3.0 billion). The ASX 200 healthcare company will receive US$40 million upfront from Regeneron for four initial programs enabling access to its radiopharmaceutical manufacturing platform.

Telix reported that it could also earn "low double-digit royalties" if it opts out of co-funding any program.

What did management say?

Commenting on the collaboration with Regeneron that's helping to boost the Telix share price today, Telix CEO and managing director Christian Behrenbruch said:

The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients.

We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers.

Israel Lowy, senior vice president clinical development unit head Oncology at Regeneron, said, "Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron's antibody technologies and oncology portfolio."

Lowy continued:

Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care.

John Lin, senior vice president of oncology & antibody technology research at Regeneron, added, "Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need."

With today's intraday lift factored in, the Telix share price is up 35.5% in 2026, racing ahead of the 1.9% year to date gains posted by the benchmark index.

The post Telix share price leaping higher today on $3 billion US news appeared first on The Motley Fool Australia.

This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.

With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:

• Domino's Pizza Enterprises Ltd (ASX: DMP) continues to be the most shorted ASX share after its short interest remained flat at 15.3%. Short sellers appear to have doubts that the pizza chain operator's turnaround strategy will succeed.
• Telix Pharmaceuticals Ltd (ASX: TLX) has short interest of 14.6%, which is up since last week. Unfortunately for short sellers, this radiopharmaceuticals company's shares stormed higher last week after the US FDA accepted its NDA for Pixclara
• Polynovo Ltd (ASX: PNV) has 14% of its shares held short, which is down since last week. This high level of short interest may be due to valuation concerns. The medical device company's shares are trading on high earnings multiples.
• Guzman Y Gomez Ltd (ASX: GYG) has short interest of 13.7%, which is down week on week. Unfortunately for short sellers, this quick service restaurant operator's shares rocketed last week after it reported a big improvement in its performance.
• Treasury Wine Estates Ltd (ASX: TWE) has seen its short interest rise to 12.5%. This wine giant is struggling due to consumer spending pressures and distributor disruption.
• Flight Centre Travel Group Ltd (ASX: FLT) has short interest of 12%, which is up slightly week on week. Short sellers may believe that travel demand could be impacted by the Middle East conflict.
• Boss Energy Ltd (ASX: BOE) has short interest of 11.7%, which is down since last week. This uranium miner's production outlook beyond 2026 is uncertain and attracting short sellers.
• Nanosonics Ltd (ASX: NAN) has short interest of 11.6%, which is down slightly since last week. This infection prevention technology company's recent performance has been disappointing. Short sellers don't appear confident a change is coming.
• DroneShield Ltd (ASX: DRO) has 11.5% of its shares held short, which is up since last week. Last week, this counter drone technology company announced the sudden exit of its CEO and chair.
• Zip Co Ltd (ASX: ZIP) has entered the top ten with short interest of 11.2%. Later this week, the buy now pay later provider will be releasing its third-quarter update. Short sellers appear to believe it could disappoint.

The post These are the 10 most shorted ASX shares appeared first on The Motley Fool Australia.

What did Telix Pharmaceuticals report?

• Entered a 50/50 global cost and profit-sharing agreement with Regeneron to co-develop radiopharmaceutical therapies targeting solid tumours.
• Receives a US$40 million upfront cash payment for four initial therapeutic programs, with the option for Regeneron to expand to four more programs.
• Potential to earn up to US$2.1 billion in development and commercial milestone payments plus low double-digit royalties if Telix opts out of co-funding any program.
• Joint development of diagnostic assets, with Telix leading commercialisation and Regeneron receiving a percentage of profits.
• Collaboration leverages Telix's expertise in radiopharmaceuticals and Regeneron's proprietary antibody platforms.

What else do investors need to know?

This collaboration brings together Telix's strong track record in radiopharmaceutical manufacturing and Regeneron's experience in antibody discovery and oncology. The combined expertise could help accelerate the development of innovative treatments for cancers with significant unmet needs, such as lung cancer.

The partnership also includes plans to create radio-diagnostic tools, supporting both targeted therapies and patient selection for optimal outcomes. Telix retains some flexibility to promote products and can choose its level of involvement for each program, potentially switching between co-funding or milestone- and royalty-based compensation.

What did Telix Pharmaceuticals management say?

Managing Director and Group CEO Christian Behrenbruch said:

The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients.

What's next for Telix Pharmaceuticals?

Telix and Regeneron will begin work on the first four programs under their collaboration, initially focusing on solid tumour targets from Regeneron's antibody pipeline. Further expansion is possible if milestones are met and both parties exercise their program options.

Telix's ability to co-develop diagnostics and therapies with Regeneron could set the stage for new approaches in precision oncology while expanding its global reach and product portfolio. Investors will be watching for progress updates and future milestones as the partnership unfolds.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal appeared first on The Motley Fool Australia.

Four ASX shares that are not letting that hold them back are listed below. Here's why they are rising:

Amaero Ltd (ASX: 3DA)

The Amaero share price is up 5% to 32 cents. This has been driven by news that the high-value refractory and titanium alloy powders provider has entered a master purchasing agreement that includes a purchase order for titanium alloy powders with a value of $7.8 million. Amaero's chair and CEO, Hank J. Holland, commented: "Commercial activity across both segments of Amaero's business is strong. We are excited to secure a contract for titanium powder shipments in FY2027 that approximates total titanium powder sales in FY2026. We have been advancing numerous titanium powder opportunities over the past 6-12 months with several opportunities potentially exceeding 100 tonnes of annual demand."

Mesoblast Ltd (ASX: MSB)

The Mesoblast share price is up 4.5% to $2.12. This appears to have been driven by bargain hunters swooping in following a pullback in the biotechnology company's shares this week. One broker that is likely to approve of this buying is Bell Potter. It currently has a speculative buy rating and $4.45 price target on its shares. This is more than double its current share price.

Telix Pharmaceuticals Ltd (ASX: TLX)

The Telix Pharmaceuticals share price is up 5.5% to $14.39. Investors have been buying the radiopharmaceuticals company's shares following the release of a major update this morning. Telix revealed that the US FDA has accepted its New Drug Application for TLX101-Px (Pixclara). It is a PET agent for imaging brain cancer (glioma). The US FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of 11 September 2026. This essentially means that Telix will find out if it will be approved within the next five months.

Tivan Ltd (ASX: TVN)

The Tivan share price is up 6% to 34.2 cents. This morning, this mineral exploration company announced that it has located high-grade copper-gold mineralisation across multiple sites at the Baucau and Ossu Projects in the Democratic Republic of Timor-Leste. Tivan's executive chair, Grant Wilson, commented: "We are very pleased to share these results today, that will resonate deeply in Timor-Leste, particularly the discovery of high-grade gold. Tivan will be working closely with community and stakeholders in the Ossu and Baucau regions in the months ahead to consolidate our social license to operate and to plan forward works."

The post Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today appeared first on The Motley Fool Australia.

Heading into the Friday lunch hour, two of the S&P/ASX 200 Index (ASX: XJO) stocks are outperforming the 0.4% losses posted by the benchmark index at this time, while one is trailing those losses.

So, which blue-chip stocks are catching ASX investor interest today?

Read on!

Fortescue shares dip on green energy news

Turning to Fortescue shares first, shares in the ASX 200 iron ore giant are down 2.1% at the time of writing, trading for $20.11 each.

This morning, the miner reported on a major milestone in its journey to eliminate diesel from large-scale industry.

The company said it is accelerating the delivery of the world's first industrial, fully integrated green energy grid at a scale "comparable to a city".

Fortescue noted that diesel fuel is 100% imported and "subject to extreme price volatility, unreliability and hardship". The company said the industry's diesel use results in billions of dollars in taxpayer-funded subsidies.

The ASX 200 miner expects to save US$100 million in fossil fuel costs by next year. Once its decarbonisation program is fully complete, the company expects C1 unit costs to come down by at least another US$2 to US$4 per wet metric tonne.

Fortescue shares are up 33.4% in 12 months, not including dividends.

Which brings us to…

Telix shares leap on US FDA acceptance

Telix shares are once more leaping onto investors' radars today.

Shares in the ASX 200 diagnostic and therapeutic product developer are up 7.3% at the time of writing, swapping hands for $14.63 apiece.

Investors have been bidding up Telix shares after the company announced that the United States Food and Drug Administration has accepted its resubmitted New Drug Application (NDA) for TLX101-Px1, the company's glioma (brain cancer) imaging agent.

"The FDA's acceptance of our NDA resubmission is an important milestone for Telix," Kevin Richardson, CEO Telix Precision Medicine, said.

"We appreciate the FDA's constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients," Richardson added.

Telix shares are down 44.9% over 12 months.

Magellan shares gain on $1.6 billion merger update

Like Telix and Fortescue shares, Magellan is making headline news today following a major announcement.

Magellan shares are up 1.3% at $9.46 apiece after the ASX 200 funds manager updated the market on its proposed full merger with Barrenjoey Capital Partners.

Magellan said it will acquire all of the remaining shares in Barrenjoey in a merger that values Barrenjoey at $1.62 billion.

Magellan shares are up 30.4% in 12 months, not including dividends.

The post Why Magellan, Telix and Fortescue shares are grabbing headlines on Friday appeared first on The Motley Fool Australia.

At the time of writing, they are up 4% to $14.17 after a major regulatory update in the United States.

The radiopharmaceuticals company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), which is a potential imaging agent for brain cancer.

So, is this a buying opportunity for investors?

A major milestone, but not the finish line

The US FDA acceptance is a significant step forward for Telix.

According to the company, the regulator has now assigned a PDUFA goal date of 11 September, which sets a clear timeline for a potential approval decision.

This is important because it moves the product further along the regulatory pathway and reduces uncertainty around timing.

However, it is worth noting that acceptance is not approval.

There is still a review process ahead, and while the outlook may be positive, regulatory risk remains. Investors should be mindful that outcomes are not guaranteed.

Strong broker support adds confidence

Despite the risks, brokers appear optimistic about Telix's outlook.

UBS recently placed a buy rating on the company with a $31.00 price target, suggesting that Telix shares could more than double in value from current levels.

Bell Potter is also positive and highlighted the importance of this regulatory catalyst. Earlier this week, it said:

The major short term catalyst is the regulatory update for TLX101 (Pixclara). The company has re-submitted the NDA and is now awaiting confirmation that the resubmission is accepted for review (which is a virtual certainty) at which time the FDA will also publish a PDUFA date. We expect a review period of 6 to 8 months, hence earliest possible approval is 4Q CY26.

The broker also pointed to broader progress across the pipeline. It adds:

The company continues to make good progress on multiple pipeline products. Short term news flow includes acceptance by the FDA of the resubmitted NDA for Pixclara and the amendment to the IND for TLX591 (prostate cancer Tx). We maintain our Buy rating. FY26 EBITDA is increased by ~US$21m to US$55.3m.

This combination of near-term catalysts and improving earnings expectations is helping support the investment case according to the broker.

So much so, it put a buy rating and $19.00 price target on its shares. This implies potential upside of 34% for investors from current levels.

Should you buy Telix shares?

The FDA acceptance is a meaningful milestone that brings Telix closer to unlocking additional value from its pipeline. Combined with bullish brokers and strong momentum across its broader portfolio, the outlook appears encouraging.

However, investors should remember that regulatory approvals are never guaranteed, and volatility is likely along the way. Nevertheless, this could be a good time to consider a patient investment in the radiopharmaceuticals company.

The post Should you buy Telix shares after its big US news? appeared first on The Motley Fool Australia.

Shares in the S&P/ASX 200 Index (ASX: XJO) diagnostic and therapeutic product developer closed yesterday trading for $13.64. In early morning trade on Friday, shares are changing hands for $14.14 apiece, up 3.7%.

For some context, the ASX 200 is down 0.6% at this same time.

With today's intraday lift factored in, Telix shares are now up an impressive 31.4% since market close on 11 March.

Here's what's piquing ASX investor interest today.

Telix shares jump on FDA acceptance

Telix shares are marching higher after the company announced that the United States Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px1.

TLX101-Px1, or Pixclara, is the company's glioma (brain cancer) imaging agent.

The FDA is aiming for a Prescription Drug User Fee Act (PDUFA) date on 11 September.

That date is achievable, as Pixclara holds both Orphan Drug and Fast Track designations in the US.

The company said that the FDA approval of Pixclara will help meet the significant unaddressed medical need for the characterisation of recurrent or progressive glioma from treatment-related changes in both adult and paediatric patients.

Telix noted that neuroimaging of glioma with 18F-FET (a radioactive imaging tracer) is already broadly recommended in international clinical practice guidelines.

FDA approval would open up the huge US medical market for Pixclara. However, Telix said it is not yet including any potential revenue from future sales in its full-year FY 2026 financial guidance.

What did management say?

"The FDA's acceptance of our NDA resubmission is an important milestone for Telix," Kevin Richardson, CEO Telix Precision Medicine, said. "We appreciate the FDA's constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients."

Commenting on the FDA acceptance helping to boost Telix shares today, Thomas Hope – Vice Chair, Department of Radiology and Biomedical Imaging at the University of California, San Francisco – said:

There remains a critical unmet need in improving our ability to image residual glioma after treatment. We have worked with Telix for the last three years to help leverage our clinical data to help make FET-PET9 available to patients in the United States.

Patrick Wen, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added:

Distinguishing tumour progression from treatment-related change remains one of the most challenging aspects of glioma care. PET imaging with 18F-FET is an important tool in clinical practice worldwide, and the FDA's acceptance of this application is a meaningful step toward broader access for patients and clinicians in the United States.

With today's intraday gains factored in, Telix shares remain down 46.8% over 12 months.

The post Up 31% in a month, why are Telix shares lifting off again on Friday? appeared first on The Motley Fool Australia.

The S&P/ASX 200 Health Care Index (ASX: XHJ) has fallen almost 17% year to date. 

However, there are opportunities to find value for investors. 

Let's look at three ASX healthcare shares drawing positive outlooks from experts. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. 

This process treats cancerous or diseased cells, an alternative approach to many cancer therapies, which also attack healthy tissue at the same time.

Telix shares have rebounded over the past couple of months, rising 55% since mid February. 

Telix shares rose in March largely because several value-driving catalysts hit at once, improving both fundamentals and investor sentiment.

However, they remain down 48% over the last year. 

In good news for investors, brokers are expecting Telix shares to recover even further. 

Recently, Bell Potter retained its buy rating and $19 price target on this radiopharmaceuticals company's shares. 

From yesterday's closing price of $13.64, this indicates a further upside of roughly 39%. 

Mayne Pharma Group Ltd (ASX: MYX)

Mayne Pharma Group is another ASX healthcare stock that is down significantly from yearly highs. 

It has fallen 32% year to date. 

This includes a 6% decline yesterday, as investors may have reacted negatively to fresh tariff worries.

However, the company is confident the new tariffs will have "no material impact" on its FY27 earnings profile.

The stock price closed yesterday at $2.16, and after the recent fall, it may be another value play.

Two analysts' forecasts via TradingView have an average one-year price target of $5.75 on the stock, indicating more than 160% upside. 

EBR Systems Inc (ASX: EBR)

EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. 

The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

It is down roughly 30% year to date. However, it is also drawing positive ratings from brokers. 

Yesterday, the company released a preliminary version of its operating metrics. 

The report showed strong Q1 2026 growth in commercial cases.

This prompted Bell Potter to release updated guidance on this ASX healthcare stock along with a price target of $2, indicating a potential 194% rise. 

The post Where is the value amongst ASX healthcare shares? appeared first on The Motley Fool Australia.

What did Telix Pharmaceuticals report?

• The US FDA accepted Telix's NDA for TLX101-Px (Pixclara®), a PET agent for imaging brain cancer (glioma)
• The Prescription Drug User Fee Act (PDUFA) goal date is 11 September 2026
• TLX101-Px holds Orphan Drug and Fast Track designations in the US
• No FY 2026 revenue guidance has been assigned to TLX101-Px pending approval
• TLX101-Px aimed at addressing an unmet medical need in both adult and paediatric glioma cases

What else do investors need to know?

The FDA's acceptance of the Telix NDA marks a key step toward potential commercialisation of TLX101-Px in the United States. This diagnostic agent aims to improve the differentiation between recurrent glioma and treatment-related changes, a persistent challenge in neuro-oncology.

TLX101-Px is expected to complement Telix's broader LAT1-targeting therapeutic pipeline, notably the TLX101-Tx therapy under investigation in the IPAX-BrIGHT clinical trial. There are currently no marketing authorisations for TLX101-Px or TLX101-Tx in any region.

Telix has reaffirmed that FY 2026 guidance does not anticipate revenue for TLX101-Px, pending the FDA decision. The product could provide both clinical impact and financial upside if approved in the future.

What's next for Telix Pharmaceuticals?

Investors can expect further updates as Telix works with the FDA ahead of the September 2026 goal date for TLX101-Px. The company is also advancing late-stage trials for related therapies, aiming to build a broader radiopharmaceutical portfolio for oncology and rare diseases.

Looking ahead, a successful approval could see Telix expand its presence in the US diagnostics market while pursuing commercial opportunities for both imaging and therapeutic candidates.

Telix Pharmaceuticals share price snapshot

Over the past year, Telix Pharmaceuticals shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: FDA accepts Pixclara NDA appeared first on The Motley Fool Australia.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Guzman Y Gomez Ltd (ASX: GYG)

According to a note out of Morgans, its analysts have retained their buy rating on this burrito seller's shares with an improved price target of $26.70. This follows the release of a third-quarter update that impressed the broker. It highlights that Guzman Y Gomez delivered a meaningful acceleration in Australian comparable store sales growth, providing tangible evidence that the business is executing well against a challenging consumer backdrop. It also points out that transaction growth continued to outpace comparable store sales growth. This maintains its strategy to be volume and frequency-led rather than price-driven. The Guzman Y Gomez share price is fetching $19.50 at the time of writing.

Lovisa Holdings Ltd (ASX: LOV)

A note out of UBS reveals that its analysts have upgraded this fashion jewellery retailer's shares to a buy rating with a $26.00 price target. UBS highlights that Lovisa's shares have fallen heavily this year amid concerns over slower store growth, softer like-for-like sales in the local market, and ongoing losses from the new Jewells store brand. However, the broker believes much of this risk is now priced in. Furthermore, it thinks the resilience of Lovisa's youth-focused, low price point offering is underappreciated by the market, and expects management to prevent sustained losses from Jewells either by fixing the business or considering a closure. The Lovisa share price is trading at $23.96 this afternoon.

Telix Pharmaceuticals Ltd (ASX: TLX)

A note out of Bell Potter reveals that its analysts have retained their buy rating and $19.00 price target on this radiopharmaceuticals company's shares. This follows the release of a solid first-quarter sales update this week. Bell Potter was pleased with Telix's update and believes it leaves the company well-placed to achieve its guidance in FY 2026. In addition, it highlights that Telix continues to make good progress on multiple pipeline products. It also sees major short term share price catalysts on the horizon. This includes the potential acceptance by the FDA of the resubmitted NDA for Pixclara and the amendment to the IND for TLX591. The Telix share price is fetching $13.83 at the time of writing.

The post Top brokers name 3 ASX shares to buy today appeared first on The Motley Fool Australia.